TW200631609A - Enteric coated bead comprising ixabepilone, and preparation and administration thereof - Google Patents

Enteric coated bead comprising ixabepilone, and preparation and administration thereof

Info

Publication number
TW200631609A
TW200631609A TW094140483A TW94140483A TW200631609A TW 200631609 A TW200631609 A TW 200631609A TW 094140483 A TW094140483 A TW 094140483A TW 94140483 A TW94140483 A TW 94140483A TW 200631609 A TW200631609 A TW 200631609A
Authority
TW
Taiwan
Prior art keywords
enteric coated
ixabepilone
coated bead
administration
preparation
Prior art date
Application number
TW094140483A
Other languages
English (en)
Chinese (zh)
Inventor
Ismat Ullah
Gary James Wiley
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of TW200631609A publication Critical patent/TW200631609A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
TW094140483A 2004-11-18 2005-11-17 Enteric coated bead comprising ixabepilone, and preparation and administration thereof TW200631609A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62897004P 2004-11-18 2004-11-18

Publications (1)

Publication Number Publication Date
TW200631609A true TW200631609A (en) 2006-09-16

Family

ID=35976527

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094140483A TW200631609A (en) 2004-11-18 2005-11-17 Enteric coated bead comprising ixabepilone, and preparation and administration thereof

Country Status (25)

Country Link
US (1) US20060153917A1 (enExample)
EP (2) EP1817013B1 (enExample)
JP (1) JP2008520696A (enExample)
KR (1) KR20070084325A (enExample)
CN (1) CN101083978A (enExample)
AR (1) AR052142A1 (enExample)
AT (1) ATE397442T1 (enExample)
AU (1) AU2005306464A1 (enExample)
BR (1) BRPI0518286A2 (enExample)
CA (1) CA2588400A1 (enExample)
DE (1) DE602005007376D1 (enExample)
DK (1) DK1817013T3 (enExample)
ES (1) ES2306278T3 (enExample)
HR (1) HRP20080349T3 (enExample)
IL (1) IL183116A0 (enExample)
MX (1) MX2007005763A (enExample)
NO (1) NO20072388L (enExample)
PE (1) PE20061058A1 (enExample)
PL (1) PL1817013T3 (enExample)
PT (1) PT1817013E (enExample)
RU (1) RU2349319C1 (enExample)
SI (1) SI1817013T1 (enExample)
TW (1) TW200631609A (enExample)
WO (1) WO2006055740A1 (enExample)
ZA (1) ZA200703955B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101091725A (zh) 2006-06-23 2007-12-26 天津天士力制药股份有限公司 一种中药颗粒及其制备方法
US20110217426A1 (en) * 2010-03-04 2011-09-08 Perry Stephen C Enteric coating composition
SI3117709T1 (sl) 2010-03-12 2018-12-31 Genzyme Corporation Kombinirana terapija za zdravljenje raka dojke
US9156189B2 (en) 2010-10-01 2015-10-13 The Johns Hopkins University Systems and methods for high-throughput microfluidic bead production
US8808736B2 (en) 2011-02-11 2014-08-19 Zx Pharma, Llc Enteric coated multiparticulate controlled release peppermint oil composition and related methods
US8911780B2 (en) 2011-02-11 2014-12-16 Zx Pharma, Llc Multiparticulate L-menthol formulations and related methods
AU2012214553B2 (en) 2011-02-11 2015-07-09 Sociétés des Produits Nestlé S.A. Multiparticulate L-menthol formulations and related methods
HUE042996T2 (hu) * 2013-04-23 2019-07-29 Zx Pharma Llc Bélben oldódó bevonatú, fehérjetartalmú alapbevonattal ellátott, több részecskét tartalmazó készítmény

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4713246A (en) * 1984-03-19 1987-12-15 Bristol-Myers Company Etoposide oral dosage form
US6537579B1 (en) * 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US6288237B1 (en) * 1995-11-17 2001-09-11 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Epothilons C and D, preparation and compositions
JP4090529B2 (ja) * 1996-01-24 2008-05-28 フロイント産業株式会社 乳糖の球形粒及びその製造方法
US6011029A (en) 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
JP4205168B2 (ja) * 1996-10-02 2009-01-07 ノバルティス アクチエンゲゼルシヤフト ピリミジン誘導体およびその製造法
CN100344627C (zh) * 1996-11-18 2007-10-24 生物技术研究有限公司(Gbf) 埃坡霉素c、其制备方法以及作为细胞抑制剂和植物保护剂的应用
FR2759293B1 (fr) * 1997-02-11 1999-04-30 Ethypharm Lab Prod Ethiques Microgranules contenant du cisplatine, procede de fabrication, preparation pharmaceutique et utilisation en polychimiotherapie ou en association avec une radiotherapie
NZ337195A (en) * 1997-02-25 2001-05-25 Biotechnolog Forschung Gmbh Epothilones with a modified side chain
GB9801231D0 (en) 1997-06-05 1998-03-18 Merck & Co Inc A method of treating cancer
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6040321A (en) 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6399638B1 (en) * 1998-04-21 2002-06-04 Bristol-Myers Squibb Company 12,13-modified epothilone derivatives
US6498257B1 (en) * 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
US7122207B2 (en) * 1998-05-22 2006-10-17 Bristol-Myers Squibb Company High drug load acid labile pharmaceutical composition
UA69413C2 (uk) * 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
DE19826988A1 (de) * 1998-06-18 1999-12-23 Biotechnolog Forschung Gmbh Epothilon-Nebenkomponenten
UA73092C2 (uk) * 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
US5997905A (en) * 1998-09-04 1999-12-07 Mcneil-Ppc Preparation of pharmaceutically active particles
JP2002526400A (ja) * 1998-10-01 2002-08-20 パウダージェクト リサーチ リミテッド 無針シリンジにおける使用のためのスプレー被覆した微小粒子
CZ20012951A3 (cs) * 1999-02-18 2001-11-14 Schering Aktiengesellschaft 16-Halogensubstituované deriváty epothilonu, způsoby jejich výroby a jejich farmaceutické pouľití
ATE254615T1 (de) * 1999-02-22 2003-12-15 Biotechnolog Forschung Gmbh C-21 modifizierte epothilone
US6518421B1 (en) * 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
CN1388758A (zh) * 2000-08-09 2003-01-01 灵药生物技术有限公司 抗结核病药物的新颖的药学组合物及其制备方法
UA75365C2 (en) 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
PL362225A1 (en) * 2000-09-22 2004-10-18 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Triazolo-epothilones
ATE279552T1 (de) 2000-09-26 2004-10-15 Enthone Omi Deutschland Gmbh Verfahren zur selektiven metallisierung dielektrischer materialien
EP1353668B1 (en) * 2001-01-25 2008-03-19 Bristol-Myers Squibb Company Processes for the preparation of pharmaceutical preparations containing epothilone analogues for the treatment of cancer
NZ526871A (en) * 2001-01-25 2006-01-27 Bristol Myers Squibb Co Pharmaceutical dosage forms of epothilones for oral administration
CN1489466A (zh) * 2001-01-25 2004-04-14 ����˹�ж�-����˹˹������˾ 包含埃博霉素类似物的非肠道制剂
MXPA03007394A (es) 2001-02-20 2003-12-04 Bristol Myers Squibb Co Tratamiento de tumores refractarios mediante uso de derivados de epotilona.
CN1610549A (zh) * 2001-02-20 2005-04-27 布里斯托尔-迈尔斯斯奎布公司 用于治疗难治肿瘤的埃坡霉素衍生物
CA2440555A1 (en) 2001-03-14 2002-09-19 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
JP2004532888A (ja) * 2001-06-01 2004-10-28 ブリストル−マイヤーズ　スクイブ　カンパニー エポチロン誘導体
JP4645789B2 (ja) * 2001-06-18 2011-03-09 Ｊｓｒ株式会社 ネガ型感放射線性樹脂組成物
WO2003077903A1 (en) * 2002-03-12 2003-09-25 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
DK1483251T3 (da) * 2002-03-12 2010-04-12 Bristol Myers Squibb Co C3-cyano-epothilon-derivater
TW200403994A (en) * 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
TW200400191A (en) * 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
US7008936B2 (en) 2002-06-14 2006-03-07 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
AU2003256157A1 (en) * 2002-08-05 2004-02-23 Dsm Ip Assets B.V. Oral dosage forms of water insoluble drugs and methods of making the same
JP2006504743A (ja) * 2002-10-09 2006-02-09 コーザン バイオサイエンシス インコーポレイテッド 治療製剤
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
US20060134214A1 (en) * 2004-11-18 2006-06-22 Ismat Ullah Enteric coated bead comprising epothilone or epothilone analog, and preparation and administration thereof

Also Published As

Publication number Publication date
KR20070084325A (ko) 2007-08-24
DK1817013T3 (da) 2008-10-13
PE20061058A1 (es) 2006-10-13
AR052142A1 (es) 2007-03-07
EP1958625A1 (en) 2008-08-20
NO20072388L (no) 2007-06-14
CN101083978A (zh) 2007-12-05
PL1817013T3 (pl) 2009-01-30
AU2005306464A1 (en) 2006-05-26
PT1817013E (pt) 2008-08-07
DE602005007376D1 (de) 2008-07-17
SI1817013T1 (sl) 2008-12-31
ES2306278T3 (es) 2008-11-01
HK1106713A1 (en) 2008-03-20
EP1817013B1 (en) 2008-06-04
MX2007005763A (es) 2007-07-20
IL183116A0 (en) 2007-09-20
CA2588400A1 (en) 2006-05-26
HRP20080349T3 (hr) 2009-01-31
US20060153917A1 (en) 2006-07-13
WO2006055740A1 (en) 2006-05-26
ZA200703955B (en) 2008-08-27
EP1817013A1 (en) 2007-08-15
RU2349319C1 (ru) 2009-03-20
BRPI0518286A2 (pt) 2008-11-11
JP2008520696A (ja) 2008-06-19
ATE397442T1 (de) 2008-06-15

Similar Documents

Publication Publication Date Title
IL171291A (en) Homogeneous thermoreversible gel film comprising kappa-2 carrageenan, process for its manufacture, soft capsules and solid forms made thereof
IL210378A0 (en) Tumor associated antigen, peptides thereof, and use of same as ati-tumor vaccines
EP1402256A4 (en) USE OF P-CADHERIN AS TARGET IN ANTICANCER THERAPY
AU2003232330A1 (en) Method of preparing microparticles
JO2464B1 (en) Formulas contain actinacidine and binary sugars
AU2003291354A1 (en) Methods and compostions for therapeutic use of rna interference
TW200631609A (en) Enteric coated bead comprising ixabepilone, and preparation and administration thereof
EP4238958A4 (en) 2-CYANOACRYLATE COMPOUND, METHOD FOR PREPARING IT AND ITS USE
AU2003271021A1 (en) Immunogen for preparation of therapeutic vaccines or drugs for treatment of hepatitis b and the producing method and use thereof
GB2402402B (en) Substrate for immobilizing physiological material, and a method of preparing the same
AU2003289603A1 (en) Tumor vaccine
AU2000279747A1 (en) Emulsion of perfluororganic compounds for medical purposes, method for producingsaid emulsion and methods for curing and preventing diseases with the aid of the emulsion
EP1701718A4 (en) SUBSTITUTED MELATONIN DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND METHOD OF ADMINISTRATION
MXPA03007036A (es) Metodo de terapia para cancer.
PL359208A1 (en) New derivatives of quinosoline, method of production of new derivatives of quinosoline and pharmaceutical preparations
AU2002365511A1 (en) Quinoline derivatives, process for preparing them and use for the treatment of diseases mediated by s-cd23
AU2002233407A1 (en) 2-arylimino-2,3-dihydrothiazole derivatives, methods for preparing them and therapeutic use thereof
AU2003264319A1 (en) New tumor antigen vaccine and producing method and vaccine composition
AU2024207684A1 (en) Linkers, drug linkers and conjugates thereof and methods of using the same
EP1711619A4 (en) INTEGRATED VIRUS COMPLEXES, METHOD FOR THE MANUFACTURE THEREOF, VACCINES CONTAINING THEM AND METHOD FOR THE USE THEREOF
AU2002365104A1 (en) Method for the diagnosis of breast cancer diseases, associated peptides and the uses thereof
AU2003303815A1 (en) Alanines compounds, method of preparing them and their use
AU2002326318A1 (en) Targeting tumor cell antigens: antibodies useful for the diagnosis, prognosis, and treatment of cancer
HK40101679B (zh) 喜树碱类化合物及其制备方法和应用
HK40101679A (zh) 喜树碱类化合物及其制备方法和应用